MUW researchers from the Department of Immunology headed by Prof. Jakub Gołąb and Polish biotechnological company OncoArendi identified a novel mechanism of antitumor immune responsiveness by mitigating arginase (ARG1) activity. This groundbreaking research has been published in the latest issue of Nature Communications.
Researchers from OncoArendi and MUW’s Department of Immunology developed an arginase inhibitor called OATD-02. In vivo testing showed that the negative effects of ARG1 enzyme can be mitigated to suppress tumor growth in ovarian cancer (OvCa). OATD-02 phase I clinical trials are planned for next year.
Information and Promotion Office
Translation: Delfina Święćkowska
Department of International Relations, Development and Promotion